Yi Li, a distinguished professor specializing in horticultural plant breeding and biotechnology at the University of Connecticut’s College of Agriculture, Health, and Natural Resources, has pioneered transformative techniques in genome editing. Li’s work tackles the profound challenge of reducing undesirable regulatory complications associated with traditional transgenic plants. His team’s breakthroughs promise to revolutionize how genome editing is applied, especially in economically vital crops.

Genome editing, exemplified by technologies such as CRISPR-Cas9, allows precise modifications to plants’ inherent genetic material. This technology circumvents the randomness of older breeding methods by targeting specific genes responsible for traits like drought resistance or heat tolerance. Despite this precision, the current standard methodology introduces foreign DNA sequences, including CRISPR components like Cas9, into plant cells. Consequently, edited plants often remain classified as GMOs, triggering strict regulatory measures worldwide.

The core challenge stems from the necessity to transiently integrate CRISPR-related genetic elements for editing while avoiding permanent insertion of foreign DNA. Conventional protocols produce transgenic plants that harbor stable foreign genes, complicating regulatory approval and public acceptance, and limiting rapid deployment at scale. In this context, Li’s research offers novel solutions that transcend existing bottlenecks by eliminating stable transgene integration.

In 2018, Li and colleagues introduced an innovative, transgene-free genome editing strategy employing Agrobacterium-mediated transient expression. This method harnesses Agrobacterium tumefaciens bacteria to transiently deliver CRISPR constructs into plant cells without permanently embedding foreign DNA into the plant genome. The transient CRISPR activity induces desired genetic edits before the bacterial DNA and associated transgenes are lost naturally through cell division, producing non-GMO edited plants.

This transient editing technique is exceptionally relevant for perennial crops or plants reproduced vegetatively, where traditional breeding cycles are prolonged. By bypassing stable transgene incorporation, the method significantly hastens the generation of edited plants, aligning with industry needs for rapid crop improvement while circumventing GMO classification constraints in many jurisdictions.

Despite promising prospects, initial iterations of transient editing faced efficiency limitations, particularly regarding the selection of successfully edited cells. Li and his collaborators have now driven substantial advances in this area. Their latest work, recently published in the high-impact journal Horticulture Research, demonstrates a marked enhancement in editing efficiency using citrus plants as an experimental model.

The research addresses a longstanding technical obstacle — differentiating plants transiently expressing CRISPR genes from uninfected cells during the editing window. By introducing kanamycin, an antibiotic, for a brief three-to-four-day selection period during Agrobacterium infection, they leveraged linked CRISPR gene expression to confer temporary antibiotic resistance. This approach effectively suppresses non-infected cells, enriching the population of edited cells without permanently introducing antibiotic resistance genes.

Remarkably, this chemical selection scheme elevated the genome editing efficiency by a factor of seventeen compared to Li’s prior 2018 protocol. This leap in editing performance not only reduces time and resource expenditure but also expands the method’s applicability across diverse crop species beyond citrus, heralding new opportunities for agriculture innovation.

Citrus crops, critically threatened by Huanglongbing disease (also known as citrus greening), epitomize urgent agricultural challenges. This devastating bacterial disease has decimated nearly 70% of Florida’s citrus trees, severely impacting U.S. citrus production. Developing genome-edited citrus variants with innate resistance offers a potential lifeline, and Li’s enhanced transgene-free editing platform could accelerate these vital breeding programs.

Beyond citrus, the implications of this technology span a broad spectrum of agricultural commodities. The capability to generate non-GMO genome-edited plants rapidly addresses regulatory bottlenecks and public concerns, facilitating commercialization and adoption. The method’s simplicity and scalability make it an attractive alternative to more complex or time-intensive transgene-free editing methods currently available.

Furthermore, Li’s refined approach exemplifies how biochemical tools and molecular biology intersect to innovate practical plant breeding solutions. The strategic use of transient antibiotic selection during bacterial-mediated transformation is a clever adaptation that elegantly balances editing efficacy, speed, and regulatory compliance.

As genome editing continues to reshape the future of agriculture, innovations like those from Li’s lab will be critical to delivering resilient, sustainable crops tailored for global food security. By circumventing the pitfalls of stable foreign DNA integration while maximizing editing precision, these advances empower breeders and farmers alike to meet tomorrow’s challenges.

In sum, this state-of-the-art Agrobacterium-mediated transient editing enhanced with short-term chemical selection stands to democratize access to gene-edited crops ideally positioned beyond existing GMO regulatory frameworks. It charts a compelling path forward for plant biotechnology with profound implications for food systems worldwide.

Subject of Research: Not applicable

Article Title: Substantial enhancement of Agrobacterium-mediated transgene-free genome editing via short-term chemical selection using citrus as a model plant

News Publication Date: 19-Sep-2025

Web References: 10.1093/hr/uhaf153

References: Li et al. (2025) Horticulture Research

Image Credits: Jason Sheldon/UConn Photo

Keywords: Crop science, Genetically modified foods

Traditional methods for engineering T cells have relied heavily on CRISPR–Cas9 technology for gene editing, which involves creating double-strand breaks in DNA to introduce desired genetic modifications. While this approach has revolutionized genome editing, it carries the inherent risk of unintended genomic alterations such as chromosomal translocations and truncations. These off-target effects pose significant safety concerns and can compromise the therapeutic efficacy of the engineered T cells. The scientific community has therefore been actively pursuing next-generation genome editing techniques that can achieve precise nucleotide changes without these hazardous outcomes.

Enter CRISPR 2.0—the evolving frontier of gene editing that encompasses base editing and prime editing technologies. Unlike the conventional CRISPR–Cas9 system, base editors enable the conversion of individual DNA bases without creating double-strand breaks, drastically reducing undesired genomic rearrangements. Prime editing further extends this capability by allowing the installation of virtually any small genetic change, including insertions, deletions, and all twelve possible base-to-base conversions, with unparalleled precision and programmability. Together, these tools represent a paradigm shift in the precision engineering of cellular immunotherapies.

The application of CRISPR 2.0 in T cell engineering is poised to tackle some of the most persistent obstacles faced by current adoptive cell therapies. One of the critical barriers has been the limited repertoire of tumor antigens that can be safely and effectively targeted. By enabling precise and multiplexed genetic alterations, CRISPR 2.0 opens avenues for broadening this antigenic spectrum, allowing T cells to recognize and combat a wider range of cancer types, including those within notoriously refractory solid tumors.

Moreover, CRISPR 2.0 methods can be harnessed to enhance the intrinsic functionality of T cells. Through the introduction of carefully defined nucleotide substitutions, researchers can modulate signaling pathways, increase resistance to inhibitory tumor microenvironments, and prolong T cell persistence after infusion. Such refinements could translate into sustained and more robust anti-cancer responses, which are vital for achieving durable remissions in patients.

An additional advantage of employing base and prime editing technologies lies in their facilitation of streamlined manufacturing processes. Traditional T cell editing and expansion workflows are intricate and time-consuming, often involving multiple manipulations that increase production costs and the risk of contamination. The heightened precision and reduced off-target effects afforded by CRISPR 2.0 can simplify these processes, potentially accelerating therapy generation and making these treatments more accessible to patients worldwide.

Currently, the field is witnessing a surge in clinical trials employing these next-generation gene editing platforms to develop precisely engineered cellular therapies. These trials are investigating not only the safety and efficacy but also the full therapeutic potential of CRISPR-modified T cells in tackling a spectrum of haematological and solid malignancies. As data from these studies emerge, they will inform the optimization of protocols and underpin regulatory strategies to bring these advanced therapies into standard clinical practice.

Nonetheless, bringing CRISPR 2.0-based T cell therapies from the laboratory to the clinic is not without hurdles. Key among these is ensuring the fidelity of base and prime editors in the complex genomic environment of human T cells and guarding against off-target edits at both the DNA and RNA level. Comprehensive and sensitive detection methods are essential to monitor these events during manufacturing and prior to clinical use.

In addition, the immunogenicity of the engineered T cells themselves must be rigorously assessed. As gene editing introduces non-native proteins or sequences, the host immune system might mount an immune response not only against the cancer cells but also against the therapeutic T cells, which could undermine treatment efficacy. Techniques to mitigate such immune rejection are an active area of investigation.

Moreover, the inherent heterogeneity of tumors, especially solid tumors with immunosuppressive microenvironments, poses a significant challenge that CRISPR 2.0 aims to address. By fine-tuning T cell receptors and modifying inhibitory checkpoint pathways, these advanced editors may enable T cells to better infiltrate and survive within hostile tumor niches, thereby overcoming barriers that have stymied prior generations of T cell therapies.

The ethical and regulatory landscapes surrounding these transformative technologies are also evolving rapidly. Ensuring patient safety while fostering innovation requires robust governance frameworks, transparency in clinical trial design, and international collaboration to harmonize standards. Public perception and acceptance will be critical determinants in the widespread adoption of CRISPR-engineered cellular therapies.

As we stand on the cusp of this new era, the convergence of synthetic biology, genome editing, and immunotherapy promises to redefine cancer treatment paradigms. The refinement of CRISPR 2.0 technologies is more than a technical milestone; it signifies the potential to shift clinical outcomes dramatically for patients who have previously faced limited options.

Looking forward, an interdisciplinary approach that integrates computational biology, advanced gene editing, and immunology will accelerate the design of next-generation T cell products that are safer, more effective, and customizable on a patient-by-patient basis. Machine learning algorithms coupled with high-throughput screening may guide the identification of optimal edits that synergize to overcome tumor resistance mechanisms.

In this exciting landscape, the ongoing and future clinical evaluations of CRISPR 2.0-modified T cell therapies will provide crucial insights, not just on efficacy and safety but on broader questions such as durability of response, quality of life improvements, and long-term immunological memory against cancer.

Ultimately, the promise of CRISPR base and prime editing is to democratize cellular immunotherapy, making it a viable and potent weapon against a broad array of cancers. With continued innovation and careful stewardship, these next-generation editing tools stand poised to transform the future of cancer care, turning what was once considered science fiction into clinical reality.

Subject of Research: Genetic engineering of T cell immunotherapies using CRISPR base and prime editing technologies.

Article Title: Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities.

Article References:
Petri, K., D’Ippolito, E., Künkele, A. et al. Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01072-4

Image Credits: AI Generated